ABSTRACT. A series of novel hydrogen peroxide sensitive prodrugs of methotrexate (MTX) and aminopterin (AMT) were synthesized and evaluated for therapeutic efficacy in mice with collagen induced arthritis (CIA) as a model of chronic rheumatoid arthritis (RA). The prodrug strategy selected is based on ROS-labile 4-methylphenylboronic acid promoieties linked to the drugs via a carbamate linkage or a direct C-N bond. Activation under patho-physiological concentrations of H2O2 proved to be effective and prodrug candidates were selected in agreement with relevant in vitro physicochemical and pharmacokinetic assays. Selected candidates showed moderate to good solubility, high chemical and enzymatic stability, and therapeutic efficacy comparable to the parent drugs in the CIA model. Importantly, the prodrugs displayed the expected safer toxicity profile and increased therapeutic window compared to MTX and AMT while maintaining a comparable therapeutic efficacy, which is highly encouraging for future use in RA patients.
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INTRODUCTION
Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic destructive synovitis and is associated with progressive disability, systemic difficulties, premature death, and socioeconomic costs. 1 The cause of RA remains unknown and currently no cure for the disease exists. Several studies have estimated the prevalence of RA to range between 0.5% to 1% of the adult population in developed countries, with a 3 to 1 female to male ratio. Aminopterin (1, AMT, Figure 1 ), an anti-folate drug initially developed for treatment of leukemia, was tested for RA treatment in 1951. 3, 4 Complex manufacturing, 5 unpredictable toxicities, [6] [7] [8] [9] and low therapeutic index 8, 10 led scientist to develop methotrexate (2, MTX, Figure 1 ), as an alternative antifolate for cancer therapy which later showed anti-arthritic properties as a disease modifying anti-rheumatic drug (DMARD). In 1988, low-dose MTX (LD-MTX, <30 mg in weekly pulses) was approved by the FDA for the treatment of RA and has remained the standard of care since. 11, 12 Although efficacious, the mechanisms that govern the anti-inflammatory and immunosuppressive effects of MTX in rheumatic diseases are still not completely understood. 13 Furthermore, the population of patients that will be responsive to an MTX regiment cannot be reliably predicted before initiating treatment. 14 Adverse effects and low efficacy of LD-MTX in RA are the predominant reasons for discontinuation of treatment. Side effects are usually mild, self-limiting, and/or preventable, but a subset of patients suffers from severe side-effects. Toxicities including anemia, neutropenia, stomatitis, oral ulcers, lethargy, fatigue, nodulosis, hepatic and pulmonary fibrosis, as well as renal insufficiency are associated to this drug. [15] [16] [17] [18] Additionally, progressive drug tolerance of disease, high patient variability, and pharmacokinetic inadequacies of LD-MTX suggest the need of more efficient and safer RA therapies. Prodrugs are chemically modified drugs that have either no or greatly decreased activity compared to the parent drug. Upon administration, prodrugs are activated in the body through chemical and/or enzymatic transformation into the pharmaceutically active moiety. 19 Approximately 20% of drugs approved since 2000 are prodrugs, 20 mostly designed to minimize and/or overcome unacceptable absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties of the native drug. 21 Several prodrugs, drug conjugates, and drug delivery systems for methotrexate have been reported in the literature but none of them have been approved for clinical use yet. [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] Reactive oxygen species (ROS), like H2O2, HO
• , O2 -, produced by phagocytes and neutrophils, 34 have important physiological roles in priming the immune system. 35, 36 Increasing evidence from different studies supports the relation between oxidative stress and the pathogenesis of inflammation and rheumatoid arthritis. 37, 38 In RA, oxidative stress has been described as an important mechanism in the pathogenesis of destructive proliferative synovitis. Under pathological inflammatory conditions, the extracellular concentration of H2O2, the most stable ROS, has been determined to be up to a 100-fold higher compared to healthy tissue, reaching concentrations as high as 1.0 mM. [39] [40] [41] [42] [43] [44] The presence of increased concentrations of H2O2 in the inflammatory environment can serve as the stimulus for prodrug activation in site-selective drug delivery systems. Phenylboronic acids and esters, [45] [46] [47] [48] phenylsulfonate esters, 49 thiazolidinones, 44 N- (2,5- dihydroxyphenyl)acetamides, 50 and α-boryl ethers, carbonates, and acetals 51 have been reported as useful structural motifs for hydrogen peroxide activatable prodrugs and imaging, but studies have mainly focused on their applications in oncology.
Here we propose a new approach to RA therapy based on the use of phenylboronic acidcontaining prodrugs that are inactive until activated locally in the inflammatory tissue. This mechanism secures that the biological activity is limited to regions of inflammation to facilitate a safer toxicity profile compared to AMT and MTX, and a more effective treatment due to the expected localization and accumulation in the target tissue. We have designed and synthesized a series of MTX and AMT prodrugs that are activated by disease-and tissue-specific factors like H2O2. Their physicochemical, pharmacokinetic, and drug-like properties have been evaluated in in vitro assays. Additionally, their in vivo efficacy and preliminary toxicity in the murine collageninduced arthritis model (CIA) was assessed.
RESULTS AND DISCUSSION

Synthesis of prodrugs.
The pinacolates 4b and 4c were synthesized from the corresponding 4-hydroxymethylphenyl boronic acids 3b and 3c via condensation with pinacol (Scheme 1).
Subsequently, the chloroformates 5a-c were achieved by reaction of 3a-c with phosgene. In parallel, the MTX core structure was synthesized starting with bromination of 2,4-diamino-6-(hydroxymethyl)pteridine hydrochloride (6·HCl) and alkylation of 4-methylaminobenzoic acid to form the pteoric acid 7, following the procedure described by Kralovej et al. 52 Amide coupling of 7 with dimethylglutamate hydrochloride 9·HCl, synthesized from glutamic acid 8, provided methotrexate dimethylester 10. Finally, coupling between 10 and 5a-c formed the desired prodrugs Efforts aiming for hydrolysis of the methyl esters in 11-13 using standard conditions based on alkaline hydrolysis with NaOH 53 or LiOH, 54 LiI in pyridine, 55 or enzymatic hydrolysis using a polymer supported lipase from Candida antarctica 56 were unsuccessful. Therefore a new synthetic strategy was proposed (see Scheme 2).
Starting from MTX, the synthesis of the corresponding PMB protected intermediate 14 was
achieved. Following the same procedure described for the synthesis of 11-13, coupling between 5a and 14 afforded 15, which was hydrolyzed to form the corresponding boronic acid 16. Lastly, PMB deprotection under acidic conditions afforded the prodrug 17. 57 for similar substrates. The last step consisted of alkaline hydrolysis of 24 to form the second AMT prodrug 25. These compounds represent the proposed set of phenylboronic acid-based AMT prodrugs in which the promoiety is attached to the secondary aniline group, bearing methylester protected (24) or free carboxylic acids (25) . Figure S1 and Figure S2 for examples on prodrug 17 and 25 chromatograms, respectively). Negative controls (no H2O2 addition) were performed in parallel ( Figure S3 ). The rationale behind the substitution of a hydrogen atom in the ortho-position of the phenylboronic acid promoiety by a methyl group or a fluorine atom was the reactivity towards oxidative deboronation. Interestingly, prodrugs 11-13 were activated and released 10 within less than 3 h (>95% conversion by UPLC-MS), therefore no effects on the reaction rate by ortho-substituents was observed under the conditions tested (Figure 2, left) . Furthermore, 17 was activated within the same time frame, releasing exclusively MTX, with no significant difference compared to 11-13. The plot of the formation of prodrug activation products versus time can be found in the SI ( Figure S4 ). Moreover, a concentration dependent release of drug was observed as determined in an activation assay using different concentrations of H2O2 (see Figure S5 ). The activation of AMT prodrugs 24 and 25 was also examined. Full consumption of prodrugs was observed in a similar timeframe compared to the MTX prodrugs (Figure 2 , right). AMT prodrugs did not release AMT nor 28 within the first two hours of incubation, but instead afforded the corresponding phenol intermediates 26 and 27 (Scheme 4). After 2 h of assay initiation, full disappearance of the prodrugs was observed and 26 and 27 started to slowly release AMT and 28, in a H2O2 concentration independent manner as studied in a separate assay (see Figure S5 ). Full formation of products was not observed even after 48 h of incubation. The formation of the relatively stable intermediates 26 and 27 could potentially allow them to disperse from the inflammatory environment and exert non-selective drug actions upon AMT release, unlike for the MTX-prodrugs 11-13 and 17, where phenol intermediates were not observed due to the faster selfimmolation. This will have to be further evaluated in a future study of the AMT prodrugs. (Table 1) . On the other hand, prodrugs 17 and 25 showed moderate to good solubility for predicted oral dosing in humans (55 and 48 µg/mL, respectively), although still low for animal dosing applications. The low solubility of 11-13 and 24 prompted the decision to select 17 and 25 for further in vitro studies. C were determined to 238 and 577 h, respectively, with stabilities higher than 90% after 24 h in both cases (Table 2 and Figure S6) . Secondly, the stability in SGF and SIF was studied and halflives calculated to 8 and 770 h in SGF, and 239 and 866 h in SIF for 17 and 25, respectively ( Table   2 and Figure S7 ). The shorter half-life of 17 in SGF was found to be pH-dependent rather than a result of enzymatic hydrolysis ( Figure S7 ). Thirdly, the stability in human and mouse plasma proved to be high, with 70% and 82% of 17 and 25 remaining after 24 h in human plasma, respectively, and 62% and 91% after 8 h in mouse plasma (see Figure S8 ). Their half-lives were calculated using first order kinetics and the results are shown in Table 2 . Lastly, the metabolic stability was evaluated by the determination of intrinsic clearance (CLint) in human and mouse pooled liver microsomes. Intrinsic clearance of 17 and 25 was calculated to 22 and 1.2 µL/min/mg respectively in human microsomes, while 6.4 and 2.6 µL/min/mg in mouse microsomes (Table 2 and Figure S9 ), indicating their high metabolic stability. Anti-arthritic efficacy and preliminary toxicity. The efficacy of the prodrug candidates 17
and 25 was evaluated in the collagen type-II induced arthritis (CIA) mouse model. This model has been found to be characterised by oxidative stress 58 and increased concentrations of H2O2 in the joint tissue, paws and limbs, 59, 60 hence it represents a good model for the evaluation of the prodrug concept. Prior to the in vivo analysis, the prodrug concept was evaluated in vitro for 17 and 25. To this end, the cell viability inhibition of the prodrugs against two MTX-and AMTsensitive cancer cell lines, NCI-H460 (lung cancer) and MCF-7 (breast cancer), 61 was tested. The prodrugs showed significantly reduced efficacy in the two cell lines when applied directly to the cells as compared to when they were activated by pre-incubation with non-cytotoxic concentration of H2O2 (Figures S10-S12). Additionally, the IC50 values of the pre-activated prodrugs 17 and 25
showed comparable biological activity to MTX and AMT ( Figure S13 and S14) in the two selected cancer cell lines. A detailed description of the assays can be found in the SI.
The in vivo anti-arthritic efficacy and preliminary toxicity study was performed using a therapeutic intervention set up in the CIA model and the parent drugs MTX and AMT were included as treatment controls. Vehicle control (2% DMSO in PBS), MTX (7.0 mg/kg), and equimolar doses of AMT, 17, and 25 were i.p. administered on a daily basis for two weeks, starting at onset of disease (day 27 after first immunization). Mean arthritis severity score and average animal body weight were measured three times per week. Reduced incidence of arthritis and reduction of macroscopic arthritis score was observed both for the drugs and prodrugs in comparison to the control group (vehicle) (Figure 3 , left). Additionally, remission of arthritis started to be detected at the end of the study for MTX, 17, and 25, with no statistically significant difference in efficacy between them. Interestingly, the AMT-group had to be sacrificed at day 33 due to significant toxicity measured as decreased average body weight in the group, while the AMT prodrug 25 did not show any sign of side-effects ( Figure 3 , right). Progressive weight loss was observed in the MTX-group towards the end of the study but not in the group treated with 17.
These results indicate the great potential of 17 and 25 as prodrugs of MTX and AMT, respectively, showing comparable efficacy in managing arthritis development and control of disease activity, and reducing side-effects compared to the parent drugs. Figure 3 . Suppression of CIA development in DBA/1J mice (left) after treatment with MTX (7 mg/kg) and equimolar amounts of AMT (6.8 mg/kg), 17 (9.7 mg/kg), and 25 (8.8 mg/kg) (n = 8 per group). Mice were given the indicated dose of test compound once per day, starting on day 27, and arthritis scoring was performed three times per week. Data represents mean values of arthritic score ± SEM. Statistics were calculated using a one-tailed non parametric Mann-Whitney. * p < 0.05 and ** p < 0.01 between MTX and vehicle and † p < 0.05 between 17 and vehicle. General health of mice (right) evaluated three times per week as the average body weight in groups of animals (n = 8) tested with vehicle, MTX, AMT, 17, and 25. Data represents mean values of bodyweight ± SEM. * p < 0.05 between AMT and vehicle. One animal in the vehicle and the 25 groups were sacrificed pre-termination due to high arthritis scores. The AMT group was removed at day 33 due to decline in health. AMT, aminopterin; CIA, collagen induced-arthritis; CII, collagen type-II; MTX, methotrexate.
Although no toxicity associated to prodrugs 17 and 25 has been observed in the animal assays performed, it is of relevance for future studies of the potential toxicities to also account for the release of quinone methides as prodrug activation end-product. Their reactivity and toxicity has been linked and reviewed elsewhere, 62 and prior studies have demonstrated that it is possible to modulate these factors through judicious choice of the substitution pattern on the quinone methides released. Noteworthy, quinone moieties are known in long-term use marketed drugs, 62 and newly focus on additional in vivo studies to establish optimal dosing and to map toxicity in more detail to hopefully advance these promising prodrugs into clinical evaluations.
EXPERIMENTAL SECTION
General considerations
Unless otherwise stated, commercially available reagents were used without further purification and all solvents were of HPLC quality. Reactions under nitrogen atmosphere were performed in oven-or flame-dried glassware and anhydrous solvents. Anhydrous CH2Cl2, CH3CN, THF, DMF, and toluene were obtained from Innovative Technology PS-MD-7 Pure solve solvent purification system. All reactions were monitored by thin-layer chromatography (TLC) and/or reversed-phased ultra-performance liquid chromatography mass spectrometry (RP-UPLC-MS). Analytical TLC was conducted on Merck aluminium sheets covered with silica (C60). The plates were either visualized under UV-light or stained by dipping in a developing agent followed by heating. KMnO4 (3 g in water (300 mL) along with K2CO3 (20 g) and 5%
aqueous NaOH (5 mL)) or Ninhydrin (3 g in a mixture of n-butanol (200 mL) and AcOH (6 mL))
were used as developing agents. Flash column chromatography was performed using Matrex 60 Following general procedure B using 4b (1.2 g, 4.8 mmol), the title compound 5b was afforded as a clear oil (1.5 g, >95% 
3-Fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl carbonochloridate (5c).
Following general procedure B using 4c (1.2 g, 4.8 mmol), the crude product 5c was afforded as a white solid (1.5 g, >95% 
Dimethyl (4-(((2,4-diaminopteridin-6-yl)methyl)(methyl)amino)benzoyl)-L-glutamate (10).
To a solution of 7 (3.0 g, 9.2 mmol) in anhydrous DMF (80 mL) was added Et3N (6.4 mL, 46. 2-Amino-6-(((4-((1,5-dimethoxy-1 2-Amino-6-(((4-((1,5-dimethoxy-1 
(S)-(4-((((
(S)-(4-((((2-Amino-6-(((4-((1,5-dimethoxy-1,5-dioxopentan-2 yl)carbamoyl)phenyl)(methyl)amino)methyl)pteridin-4-yl)carbamoyl)oxy)methyl)-2-fluorophenyl)boronic acid (13).
Following general procedure C using 5c ( 4-(4,4,5,5-tetramethyl-1,3 
Bis(4-methoxybenzyl) (4-(((2,4-diaminopteridin-6-yl)methyl)(methyl)amino)benzoyl)-Lglutamate (14)
.
Bis(4-methoxybenzyl) (4-(((2-amino-4-((((
(S)-(4-((((2-Amino-6-(((4-((1,5-bis((4-methoxybenzyl)oxy)-1,5-dioxopentan-2-yl)carbamoyl)phenyl)(methyl)amino)methyl)pteridin-4-yl)carbamoyl)oxy)methyl)phenyl)boronic acid (16).
Dimethyl (4-(((benzyloxy)carbonyl)amino)benzoyl)-L-glutamate (20). To a suspension of 19
(2.90 g, 10.7 mmol) in anhydrous CH2Cl2 was added 1 drop of DMF followed by thionyl chloride (3.88 mL, 53.4 mmol) and the reaction mixture was refluxed for 24 h under an N2 atmosphere.
Next, all volatiles were removed in vacuo to afford the acyl chloride as a pale yellow solid (3.1 g, >95%) which was added to a stirred mixture of 9·HCl (2.40 g, 11.3 mmol) and Et3N in anhydrous 
Physicochemical and pharmacokinetic in vitro assays
Activation of prodrugs under oxidative conditions. To a mixture of DMSO (150 μL Eppendorf Thermomixer C (1.5 mL, 1000 rpm) and samples were taken (90 μL) after 0, 1, 2, 4, and 24 h. Diclofenac (10 μL, 1 mM in DMSO) was added to the taken samples as internal standard.
Analysis of the percentage of remaining compound was performed using RP-UPLC-UV (λ= 306 nm). A negative control experiment (no pepsin or pancreatin addition) was performed in parallel.
Every assay was carried out in triplicates. as the concentration of the compounds required to cause 50% response compared to cells exposed to controls using a non-linear dose-response regression. 
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